Combination of Tamoxifen, PDE5i Reduces Curvature in Acute Peyronie Disease

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 20, 2026.

via HealthDay

WEDNESDAY, May 20, 2026 -- The combination of phosphodiesterase type 5 inhibitors (PDE5is) and the selective estrogen receptor modulator tamoxifen reduces curvature among men with acute Peyronie disease (PD), according to research published online May 14 in The Journal of Sexual Medicine.

Mohammad Shah, M.D., from University College London Hospitals, and colleagues conducted a clinical audit to examine the effect of the combination of PDE5i (50 mg sildenafil or 5 mg tadalafil once daily) and tamoxifen (20 mg twice daily) for three months in 133 men presenting with acute PD.

The researchers found that in patients who received the tamoxifen + PDE5i combination, there was a significant decrease in the curvature, while no significant change was seen in patients who received standard care. After adjustment for age and disease duration, the decrease in the curvature among patients who received the tamoxifen + PDE5i combination remained significant. Among patients receiving standard care, the curvature worsened in 30.8 percent, showed no change in 53.8 percent, and improved in 15.4 percent. Among patients receiving the tamoxifen + PDE5i combination, the curvature worsened, had no change, and improved in 9, 48.1, and 42.9 percent, respectively. Pain during erection was reported by half of the patients receiving standard care, decreasing to 26.9 percent after the intervention; 64.7 percent of the tamoxifen + PDE5i combination group had pain during erection before the intervention, decreasing to 1.5 percent after the intervention.

"These results suggest that early intervention targeting fibrosis could change how we treat Peyronie's disease," lead author Selim Cellek, M.D., Ph.D., from Anglia Ruskin University in Cambridge, England, said in a statement. "Repurposing existing drugs may allow us to move from managing symptoms to modifying the disease itself."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-21 03:09

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords